Cost-Effectiveness Analysis of Bimekizumab against Interleukin-23 Inhibitors in Patients with Plaque Psoriasis in Japan - PubMed
2 hours ago
- #Bimekizumab
- #Cost-Effectiveness Analysis
- #Psoriasis Treatment
- Bimekizumab, an IL-17A and IL-17F inhibitor, was assessed for cost-effectiveness versus IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) for moderate-to-severe plaque psoriasis in Japan.
- A lifetime Markov model showed bimekizumab generated the highest quality-adjusted life years (QALYs) and was cost-effective at a ¥5 million/QALY threshold, with ICERs ranging from ~¥3.2 to ¥4.95 million/QALY.
- Quality of life (QOL) scores, particularly for PASI 100 response, were key drivers of cost-effectiveness, with sensitivity analyses confirming robustness.
- The study supports considering bimekizumab as a first-line treatment option in Japan, based on its cost-effectiveness compared to IL-23 inhibitors.